Samuraciclib (hydrochloride hydrate)

Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride hydrate has anti-tumor effects[1][2].

Product Specifications

Product Name Alternative

CT7001 (hydrochloride hydrate) ; ICEC0942 (hydrochloride hydrate)

UNSPSC

12352005

Target

Apoptosis; CDK

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/samuraciclib-hydrochloride-hydrate.html

Purity

99.88

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O[C@H]1CNCC[C@@H]1CNC2=NC3=C(C(C)C)C=NN3C(NCC4=CC=CC=C4)=C2.Cl.O

Molecular Formula

C22H30N6O. (2.5HCl) . (3.7H2O)

Molecular Weight

552.33

References & Citations

[1]Patel H, et al. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. Mol Cancer Ther. 2018 Jun;17 (6) :1156-1166.|[2]Hazel P, et al. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study. ChemMedChem. 2017 Mar 7;12 (5) :372-380.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 2

Isoform

CDK1; CDK2; CDK4; CDK5; CDK6; CDK7; CDK9

Citation 01

EMBO J. 2025 Sep 8.|Adv Sci (Weinh) . 2024 Dec 10:e2413103.|Biochem Biophys Res Commun. 2024 Aug 28:735:150608.|Cell Death Dis. 2019 Aug 9;10 (8) :602.|Clin Cancer Res. 2024 May 1;30 (9) :1889-1905.|Proc Natl Acad Sci U S A. 2019 Jun 25;116 (26) :12986-12995. |Res Sq. 2024 Jul 29.|Structure. 2024 Jun 9:S0969-2126 (24) 00188-6.|Int J Mol Sci. 2022 Feb 24;23 (5) :2493.|J Cancer Res Clin Oncol. 2023 Jul;149 (8) :5255-5263.|mBio. 2025 Dec 10;16 (12) :e0289825.|Signal Transduct Target Ther. 2025 Nov 6;10 (1) :363.